Enhancing Cardiovascular Health in End-Stage Kidney Disease, with Maya N. Clark-Cutaia, PhD, RN
HCPLive
MAY 16, 2024
Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.
HCPLive
MAY 16, 2024
Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.
DAIC
APRIL 30, 2024
The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.
Let's personalize your content